Team Siliconindia

·  300 new jobs to be created at Novo Nordisk’s India GBS hub in 2025.

·  India centre drives AI-led drug development and digital health innovation.

·  Wegovy launch marks major step in tackling India’s rising obesity burden.

Danish drug maker Novo Nordisk plans to create 200-300 new positions in India during 2025, cementing the critical position of its Global Business Services (GBS) centre in Bengaluru as a strategic centre for innovation, operations, and clinical development.                                              

Described worldwide for its obesity drug Wegovy and diabetes sensation Ozempic, the company has almost doubled its GBS staff to 4,500 across 17 global functions within more than two years.

"This is a critical time for us, particularly with the roll-out of Wegovy in the Indian market," said John Dawber, Corporate Vice President and Managing Director of GBS at Novo Nordisk, during an interview.

Also Read- Microsoft Cuts 9,000 Jobs to Streamline Operations in Fiscal 2025

 India at the Core of Global Strategy

Novo Nordisk's India hub is now closely entrenched in AI-driven drug discovery, regulatory affairs, leadership development, and digital health innovation. In Dawber's opinion, more than 2,000 new positions have been added in the last 2.5 years. Even though short-term attention is devoted to streamlining, another 200–300 positions will be created in 2025.

The center is also part of the company's expanding pipeline in obesity and rare diseases. Wegovy was launched in India officially in June 2025, after receiving regulatory approval to treat adults with obesity or its associated comorbidities a major milestone in Novo Nordisk's foray in India's chronic disease market.

As obesity rates increase and the burden of metabolic disease grows, India is set to become a high-need market for the company's treatments.

Enabling Global Clinical and Commercial Operations

Although certain numbers were not revealed, Dawber assured that the India centre is actively involved with global teams for clinical trials, regulatory submissions, and market introduction plans for obesity and rare disease medicines.

The partnership between the Indian GBS centre and global teams facilitates co-development of medical content, which is afterwards adapted and rolled out to international markets.

It might not be exponential growth from here, but it will be rich, worthwhile, and in sync with world priorities," Dawber added.

Talent, Collaborations, and the Future

India's deep pool of medical talent and increasing digital maturity remain crucial accelerators. With more than 100,000 medical graduates annually and a worldwide reputation as the 'pharmacy of the world', India presents a strategic opportunity for healthcare innovation.

Novo Nordisk GBS has established robust academic collaborations with institutions like BITS Pilani, IIIT-Bangalore, and MAHE (Manipal). The center also closely works with local startups engaged in AI-based innovations in clinical data automation, adverse event reporting, and medical content creation.

"India is no longer merely a delivery centre it's where innovation, strategy, and leadership come together to define Novo Nordisk's future on the global stage," said Dawber.

Alltough recruitment is likely to ease slightly because of automations and workflow maximisation, Dawber is convinced of continued and genuine long-term growth from the India hub.